CytomX Therapeutics, Inc. — Director's Dealing 2021

Jun 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CytomX Therapeutics, Inc. (CTMX)
CIK: 0001501989
Period of Report: 2021-06-14

Reporting Person: McCarthy Sean A. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-14	Common Stock	M	30.00	$1.1339	Acquired	7839	Direct
2021-06-14	Common Stock	M	10	$0.945	Acquired	7849	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-14	Stock Option (Right to Buy)	$1.1339	M	30	Disposed	2021-09-20	Common Stock (30)	Direct
2021-06-14	Stock Option (Right to Buy)	$0.9450	M	10	Disposed	2023-02-25	Common Stock (10)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	193118	Indirect

Footnotes

F1: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.

F2: 100% of the shares subject to the option are fully vested and exercisable.